Literature DB >> 2885802

Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects.

S O Bergquist, S Bernander, H Dahnsjö, B Sundelöf.   

Abstract

In an open randomized study 17 patients with a positive culture for Bordetella pertussis were treated for 10 days with erythromycin (50 mg/kg/day divided in 2 doses). The bacterium could not be isolated during therapy and in only one patient was it isolated 5 days after cessation of treatment. In comparison B. pertussis was isolated 10 and 15 days after diagnosis from 10 and 4 patients, respectively, of a group of 21 untreated controls. The treated group developed significantly fewer whoops than did the control group, even though most of the individuals had reached the paroxysmal stage at diagnosis. The dose of erythromycin (ethylsuccinate and stearate preparations) gave serum concentrations about 100 times larger than the minimal inhibitory concentration of isolated bacteria and was well-tolerated. Thus adequate erythromycin treatment eliminates B. pertussis from the nasopharynx and reduces symptoms in patients having a history of pertussis of less than 14 days. Adequate dosage and length of treatment might be crucial for these results.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2885802     DOI: 10.1097/00006454-198705000-00009

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  15 in total

1.  Pertussis is increasing in unimmunized infants: is a change in policy needed?

Authors:  S Ranganathan; R Tasker; R Booy; P Habibi; S Nadel; J Britto
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

2.  Update on pertussis and pertussis immunization.

Authors:  Jung Yun Hong
Journal:  Korean J Pediatr       Date:  2010-05-31

3.  Update of epidemiology, diagnosis, and treatment of pertussis.

Authors:  J E Hoppe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

Review 4.  Treatment and prevention of pertussis by antimicrobial agents (Part II).

Authors:  J E Hoppe; A Haug
Journal:  Infection       Date:  1988 May-Jun       Impact factor: 3.553

Review 5.  Rational prescribing of antibacterials in ambulatory children.

Authors:  J E Hoppe
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

Review 6.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

7.  Comparison of erythromycin ethylsuccinate and co-trimoxazole for treatment of pertussis.

Authors:  J E Hoppe; U Halm; H J Hagedorn; A Kraminer-Hagedorn
Journal:  Infection       Date:  1989 Jul-Aug       Impact factor: 3.553

8.  Neurologic alterations in an HIV adult patient with pertussis: a case report.

Authors:  María Camila Arango-Granados; Iván Mauricio Trompa
Journal:  BMC Infect Dis       Date:  2020-07-02       Impact factor: 3.090

9.  Pertussis: The Identify, Isolate, Inform Tool Applied to a Re-emerging Respiratory Illness.

Authors:  Kristi L Koenig; Jennifer Farah; Eric C McDonald; Sayone Thihalolipavan; Michael J Burns
Journal:  West J Emerg Med       Date:  2018-12-05

10.  Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background.

Authors:  R Gonzales; J G Bartlett; R E Besser; R J Cooper; J M Hickner; J R Hoffman; M A Sande
Journal:  Ann Emerg Med       Date:  2001-06       Impact factor: 5.721

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.